Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1692596

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1692596

Assisted Reproductive Technology Market by Technology (In Vitro Fertilization, Artificial Insemination), Type (Instruments (Incubators), Media (Cryopreservation), Supplements, Consumables), Patient Type (Male, Female), End User - Global Forecast to 2030

PUBLISHED:
PAGES: 321 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The assisted reproductive technology market is projected to reach USD 6.02 Billion by 2030 from USD 4.29 Billion in 2025 at a CAGR of 7.0% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsBy Technology, Type, Patient Type, Care Setting and Region
Regions coveredNorth America, Europe, APAC, LATAM, GCC Countries

Increasing rates of infertility due to delayed conception, altered lifestyles, and growing awareness of fertility treatment are driving the assisted reproductive technology (ART) market. Further impetus to market growth is coming from improvements in medical technology, improved treatment success rates with in-vitro fertilization (IVF), and favorable government policies. But some of these limitations are the cost of treatment, ethical and legal issues, and health risks associated with ART procedures. Inadequacy of fertility treatment in developing nations and physical and psychological stress of ART also limit market growth. Research and development are, in spite of these limitations, enhancing the price and effectiveness of ART treatments.

"The IVF segment is accounted for the largest share of global assisted reproductive technology market."

IVF has become the ART procedure of choice over other treatments due to innovations like time-lapse imaging, embryo freezing, and preimplantation genetic testing (PGT), which have greatly enhanced IVF success. Global demand for IVF has also been driven by delayed pregnancy, rising infertility, and greater awareness of fertility treatment. IVF domination of the market is also driven by greater medical tourism practice, government subsidization of ART procedures, and greater numbers of fertility clinics.

Due to its high success rates, commonality of use, and ongoing technological advancements, the IVF category maintains the largest market share in the assisted reproductive technology (ART) market.

The best treatment for infertility, in vitro fertilization (IVF), can treat many different kinds of infertility problems, including unexplained infertility, male factor infertility, and older mother age.

"Fertility clinics has the largest market share in assisted reproductive technology market."

Fertility clinics enjoy the largest market share among the assisted reproductive technology market in care facilities owing to the growing demand for specialist reproductive treatments, high-technology healthcare facilities, and the increased number of infertile patients worldwide. Since ART therapies provided are heterogeneous in nature, encompassing intrauterine insemination, in-vitro fertilization, freezing eggs and sperm, and preimplantation genetic diagnosis, fertility clinics remain the preferred option for those who require fertility therapies. Expansion of private fertility clinics, government initiatives, and growing awareness regarding reproductive therapies have also driven the growth of this segment. Fertility clinics' dominance in the ART business is also complemented by the growing trend of medical tourism for affordable ART therapy in Thailand, India, and Spain.

"Asia Pacific holds the largest market share in the assisted reproductive technology market."

Asia-Pacific holds the maximum market share in the ART market due to its large population, large infertility rates, and strong awareness of fertility treatment. There is growing demand for ART treatment in the region at a rapid rate due to factors such as delayed parenthood, changing lifestyles, and high levels of stress that exacerbate fertility. Government-sponsored programs for ART funding, the proliferation of fertility clinics, and advances in reproductive technology have all contributed to the growth in the market. Key drivers are countries such as China, India, and Japan, which offer low-cost fertility treatments that are in great demand among medical tourists. Asia-Pacific's market dominance is also supported by increasing acceptance of ART as well as the increase in the affordability of healthcare and infrastructure.

A breakdown of the primary participants (supply-side) for the assisted reproductive technology market referred to for this report is provided below:

  • By Company Type: Tier 1-40%, Tier 2-30%, and Tier 3-30%
  • By Designation: C-level-55%, Director Level-27%, and Others-18%
  • By Region: North America-35%, Europe-32%, Asia Pacific-25%, Latin America- 5%, and Middle East and Africa- 1% and GCC Countries- 2%

Prominent players in this market include CooperSurgical Inc. (US), FUJIFILM Irvine Scientific (Japan), Vitrolife (Sweden), Hamilton Thorne (US), Cook Medical Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea BIOMEDX (Australia), Thermo Fisher Scientific Inc. (US), LENUS Pharma GesmbH (Austria), Zita West (UK), Kitazato Corporation (Japan), Exeltis USA, Inc. (US), Vitabiotics Ltd (UK), FertiPro NV (Belgium), and AdvaCare Pharma (US), among others.

Research Coverage:

The market study covers the assisted reproductive technology market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by type, technology, patient type, care setting and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

  • Analysis of Market Dynamics: Drivers (Increasing median age of pregnancy, Rising infertility rate, Booming fertility industry, Evolving technological landscape, Favorable government initiatives) restraints (High cost of IVF procedures, Social and ethical concerns in developing countries, Elevated risk of complications) opportunities (Growth opportunities in emerging economies, Availability of diverse range of fertility treatment options), and challenges (Reduced efficacy of infertility treatments among patients of advanced age)
  • Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the assisted reproductive technology market.
  • Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, care settings, and region.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the assisted reproductive technology market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the assisted reproductive technology market like CooperSurgical Inc. (US), FUJIFILM Irvine Scientific (Japan), Vitrolife (Sweden), Hamilton Thorne (US), Cook Medical Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea BIOMEDX (Australia), and Thermo Fisher Scientific Inc. (US).
Show more
Product Code: MD 9335

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH DESIGN
    • 2.2.1 SECONDARY RESEARCH
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY RESEARCH
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key industry insights
      • 2.2.2.3 Breakdown of primary interviews
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 SUPPLY-SIDE ANALYSIS
    • 2.3.2 BOTTOM-UP APPROACH
      • 2.3.2.1 Company revenue estimation approach
      • 2.3.2.2 Customer-based market estimation
      • 2.3.2.3 Demand-side market size estimation
      • 2.3.2.4 Growth forecast approach
  • 2.4 DATA TRIANGULATION
  • 2.5 MARKET SHARE ASSESSMENT
  • 2.6 RESEARCH ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
  • 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE AND COUNTRY
  • 4.3 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: REGIONAL MIX
  • 4.5 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing median age of pregnancy
      • 5.2.1.2 Rising infertility rate
      • 5.2.1.3 Booming fertility industry
      • 5.2.1.4 Evolving technological landscape
      • 5.2.1.5 Favorable government initiatives
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of IVF procedures
      • 5.2.2.2 Social and ethical concerns in developing countries
      • 5.2.2.3 Elevated risk of complications
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in emerging economies
      • 5.2.3.2 Availability of diverse range of fertility treatment options
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Reduced efficacy of infertility treatments for patients of advanced age
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
    • 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5 VALUE CHAIN ANALYSIS
    • 5.5.1 RESEARCH & PRODUCT DEVELOPMENT
    • 5.5.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
    • 5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • 5.6.1 PROMINENT COMPANIES
    • 5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES
    • 5.6.3 END USERS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
      • 5.9.1.1 Time-lapse technology
    • 5.9.2 COMPLEMENTARY TECHNOLOGIES
      • 5.9.2.1 Preimplantation genetic testing
    • 5.9.3 ADJACENT TECHNOLOGIES
      • 5.9.3.1 Sperm cryopreservation
      • 5.9.3.2 Oocyte cryopreservation
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE DATA ANALYSIS
    • 5.11.1 IMPORT DATA
    • 5.11.2 EXPORT DATA
  • 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.13 CASE STUDY ANALYSIS
    • 5.13.1 CASE STUDY 1: ENHANCED IVF RATES USING EMBRYOTOXICITY, PLATELET LEUKOCYTE AGGREGATES, AND NATURAL KILLER DIAGNOSIS
    • 5.13.2 CASE STUDY 2: IMPROVED EMBRYO SELECTION THROUGH AI-DRIVEN PLATFORM
    • 5.13.3 CASE STUDY 3: ASSESSMENT OF EMBRYO VIABILITY USING AI-DRIVEN SYSTEMS
  • 5.14 REGULATORY LANDSCAPE
    • 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.14.2 REGULATORY FRAMEWORK
      • 5.14.2.1 North America
        • 5.14.2.1.1 US
        • 5.14.2.1.2 Canada
      • 5.14.2.2 Europe
      • 5.14.2.3 Asia Pacific
        • 5.14.2.3.1 India
        • 5.14.2.3.2 Japan
  • 5.15 PORTER'S FIVE FORCES ANALYSIS
    • 5.15.1 THREAT OF NEW ENTRANTS
    • 5.15.2 THREAT OF SUBSTITUTES
    • 5.15.3 BARGAINING POWER OF BUYERS
    • 5.15.4 BARGAINING POWER OF SUPPLIERS
    • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.16.2 BUYING CRITERIA
  • 5.17 UNMET NEEDS
  • 5.18 REIMBURSEMENT SCENARIO
  • 5.19 IMPACT OF AI/GEN AI ON ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
    • 5.19.1 INTRODUCTION
    • 5.19.2 MARKET POTENTIAL OF AI IN ASSISTED REPRODUCTIVE TECHNOLOGY
    • 5.19.3 AI USE CASES
    • 5.19.4 KEY COMPANIES IMPLEMENTING AI
    • 5.19.5 FUTURE OF GENERATIVE AI IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET

6 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 IN VITRO FERTILIZATION
    • 6.2.1 IVF WITH ICSI
      • 6.2.1.1 Higher success rates than conventional methods to stimulate growth
    • 6.2.2 IVF WITHOUT ICSI
      • 6.2.2.1 Preferred choice for less severe infertility issues to facilitate growth
  • 6.3 ARTIFICIAL INSEMINATION
    • 6.3.1 GROWING PREFERENCE FOR MINIMALLY INVASIVE TREATMENTS TO DRIVE MARKET

7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE

  • 7.1 INTRODUCTION
  • 7.2 INSTRUMENTS
    • 7.2.1 EMBRYO INCUBATORS
      • 7.2.1.1 Need for undisturbed and protective environment throughout incubation to aid growth
    • 7.2.2 SPERM ANALYZER SYSTEMS
      • 7.2.2.1 Capability to identify fertility problems and determine appropriate interventions to fuel market
    • 7.2.3 MICROMANIPULATORS
      • 7.2.3.1 Increased adoption of micromanipulators in intracytoplasmic sperm injections and embryo biopsies to boost market
    • 7.2.4 OTHER INSTRUMENTS
  • 7.3 MEDIA
    • 7.3.1 EMBRYO CULTURE MEDIA
      • 7.3.1.1 Close resemblance to natural environment to amplify growth
    • 7.3.2 CRYOPRESERVATION MEDIA
      • 7.3.2.1 Ability to protect cells from damage to drive market
    • 7.3.3 SEMEN PROCESSING MEDIA
      • 7.3.3.1 Growing application in washing, capacitation, and sperm selection to boost market
    • 7.3.4 OVUM PROCESSING MEDIA
      • 7.3.4.1 Ability to mimic natural conditions of female reproductive tract to aid growth
  • 7.4 SUPPLEMENTS
    • 7.4.1 RISING DEMAND FOR FERTILITY-ENHANCING SUPPLEMENTS TO SUPPORT GROWTH
  • 7.5 CONSUMABLES
    • 7.5.1 CULTURE DISHES & PLATES
      • 7.5.1.1 Growing advancements in embryo incubation to drive market
    • 7.5.2 STORAGE CONTAINERS
      • 7.5.2.1 Increasing use of cryopreservation techniques to expedite growth
    • 7.5.3 CRYOVIALS & TUBES
      • 7.5.3.1 Growing trend of egg and embryo freezing for delayed parenthood to boost market
    • 7.5.4 OTHER CONSUMABLES

8 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE

  • 8.1 INTRODUCTION
  • 8.2 FEMALE PATIENTS
    • 8.2.1 RISING FEMALE INFERTILITY RATE TO AMPLIFY GROWTH
  • 8.3 MALE PATIENTS
    • 8.3.1 LIFESTYLE CHANGES AND INCREASING INCIDENCE OF LOW SPERM COUNT TO PROMOTE GROWTH

9 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 FERTILITY CLINICS
    • 9.2.1 INCREASED AVAILABILITY AND ACCESSIBILITY OF FERTILITY CLINICS TO SUSTAIN GROWTH
  • 9.3 HOSPITALS & SURGERY CLINICS
    • 9.3.1 NEED FOR ADVANCED LABORATORIES FOR GAMETE HANDLING AND ULTRASOUND MONITORING TO AID GROWTH
  • 9.4 RESEARCH INSTITUTES
    • 9.4.1 ONGOING RESEARCH FOR COST-EFFECTIVE AND ADVANCED TECHNIQUES TO STIMULATE GROWTH
  • 9.5 CRYOBANKS
    • 9.5.1 GROWING INCLINATION TOWARD FLEXIBLE TREATMENT TO FUEL MARKET

10 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 Favorable infrastructure network to encourage growth
    • 10.2.3 CANADA
      • 10.2.3.1 Growing assistance from banks for fertility treatments to fuel market
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Robust healthcare infrastructure to support growth
    • 10.3.3 UK
      • 10.3.3.1 Increasing focus on high-quality care at licensed fertility clinics to propel market
    • 10.3.4 FRANCE
      • 10.3.4.1 Growing healthcare expenditure to boost market
    • 10.3.5 ITALY
      • 10.3.5.1 Favorable regulatory guidelines to support market growth
    • 10.3.6 SPAIN
      • 10.3.6.1 Booming medical tourism to drive market
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 CHINA
      • 10.4.2.1 Increasing medical benefits for childbirth to intensify growth
    • 10.4.3 JAPAN
      • 10.4.3.1 Low fertility rates to amplify growth
    • 10.4.4 INDIA
      • 10.4.4.1 Affordable treatment options to favor growth
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Declining fertility rate to advance growth
    • 10.4.6 SOUTH KOREA
      • 10.4.6.1 Growing focus on reversing low population trend to drive market
    • 10.4.7 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Rise in aging mothers to contribute to growth
    • 10.5.3 MEXICO
      • 10.5.3.1 Growing network of state-of-the-art facilities to boost market
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 RISING HEALTHCARE SPENDING TO FOSTER GROWTH
    • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.7 GCC COUNTRIES
    • 10.7.1 IMPROVED HEALTH INFRASTRUCTURE AND BETTER AWARENESS ABOUT FERTILITY TREATMENTS TO PROPEL MARKET
    • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
  • 11.3 REVENUE ANALYSIS, 2020-2024
  • 11.4 MARKET SHARE ANALYSIS, 2024
  • 11.5 COMPANY VALUATION AND FINANCIAL METRICS
    • 11.5.1 COMPANY VALUATION
    • 11.5.2 FINANCIAL METRICS
  • 11.6 BRAND/PRODUCT COMPARISON
  • 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 11.7.1 STARS
    • 11.7.2 EMERGING LEADERS
    • 11.7.3 PERVASIVE PLAYERS
    • 11.7.4 PARTICIPANTS
    • 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 11.7.5.1 Company footprint
      • 11.7.5.2 Region footprint
      • 11.7.5.3 Type footprint
      • 11.7.5.4 Product type footprint
      • 11.7.5.5 Patient type footprint
      • 11.7.5.6 End-user footprint
  • 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 11.8.1 PROGRESSIVE COMPANIES
    • 11.8.2 RESPONSIVE COMPANIES
    • 11.8.3 DYNAMIC COMPANIES
    • 11.8.4 STARTING BLOCKS
    • 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 11.8.5.1 Detailed list of key startups/SMEs
      • 11.8.5.2 Competitive benchmarking of key startups/SMEs
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES
    • 11.9.2 DEALS
    • 11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 COOPERSURGICAL INC.
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Deals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Key strengths
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses and competitive threats
    • 12.1.2 FUJIFILM IRVINE SCIENTIFIC
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Deals
        • 12.1.2.3.2 Other developments
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Key strengths
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses
    • 12.1.3 VITROLIFE
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Deals
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Key strengths
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses and competitive threats
    • 12.1.4 THERMO FISHER SCIENTIFIC INC.
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products offered
      • 12.1.4.3 MnM view
        • 12.1.4.3.1 Key strengths
        • 12.1.4.3.2 Strategic choices
        • 12.1.4.3.3 Weaknesses and competitive threats
    • 12.1.5 COOK MEDICAL INC.
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Product launches
        • 12.1.5.3.2 Deals
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Key strengths
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses and competitive threats
    • 12.1.6 HAMILTON THORNE
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products offered
      • 12.1.6.3 Recent developments
        • 12.1.6.3.1 Deals
      • 12.1.6.4 MnM view
        • 12.1.6.4.1 Key strengths
        • 12.1.6.4.2 Strategic choices
        • 12.1.6.4.3 Weaknesses and competitive threats
    • 12.1.7 KITAZATO CORPORATION
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Deals
    • 12.1.8 ESCO MICRO PTE. LTD.
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Deals
    • 12.1.9 FERTIPRO NV
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products offered
    • 12.1.10 GENEA BIOMEDX
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products offered
      • 12.1.10.3 Recent developments
        • 12.1.10.3.1 Deals
    • 12.1.11 LENUS PHARMA GESMBH
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products offered
      • 12.1.11.3 Recent developments
        • 12.1.11.3.1 Product launches
    • 12.1.12 ZITA WEST
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products offered
    • 12.1.13 EXELTIS USA, INC.
      • 12.1.13.1 Business overview
      • 12.1.13.2 Products offered
    • 12.1.14 VITABIOTICS LTD.
      • 12.1.14.1 Business overview
      • 12.1.14.2 Products offered
    • 12.1.15 ADVACARE PHARMA
      • 12.1.15.1 Business overview
      • 12.1.15.2 Products offered
  • 12.2 OTHER COMPANIES
    • 12.2.1 FAIRHAVEN HEALTH
    • 12.2.2 SHANGHAI UNICORN MEDICAL TECHNOLOGY CO., LTD.
    • 12.2.3 GYNEMED GMBH & CO. KG
    • 12.2.4 INVITROCARE INC.
    • 12.2.5 IVFTECH
    • 12.2.6 LABIVF ASIA PTE LTD.
    • 12.2.7 COAST SCIENCE
    • 12.2.8 BIOIMAGER INC.
    • 12.2.9 SHIVANI SCIENTIFIC
    • 12.2.10 MINITUB GMBH

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
Show more
Product Code: MD 9335

List of Tables

  • TABLE 1 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 STANDARD CURRENCY CONVERSION RATES, 2019-2023
  • TABLE 3 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT TYPE, 2022-2024 (USD)
  • TABLE 4 AVERAGE SELLING PRICE TREND OF SUPPLEMENTS, BY REGION, 2022-2024 (USD)
  • TABLE 5 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 6 INNOVATIONS AND PATENT REGISTRATIONS, 2022-2024
  • TABLE 7 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020-2024 (USD THOUSAND)
  • TABLE 8 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020-2024 (USD THOUSAND)
  • TABLE 9 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 REGULATORY STANDARDS AND APPROVALS FOR ASSISTED REPRODUCTIVE TECHNOLOGY
  • TABLE 16 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS (%)
  • TABLE 18 KEY BUYING CRITERIA FOR TOP TWO END USERS
  • TABLE 19 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: CURRENT UNMET NEEDS
  • TABLE 20 MAJOR CPT CODES FOR LASER PROCEDURES IN US, 2024
  • TABLE 21 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 22 ASSISTED REPRODUCTIVE TYPE MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 23 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 24 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF WITH ICSI, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 25 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF WITHOUT ICSI, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 26 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR ARTIFICIAL INSEMINATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 27 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 28 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 29 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 30 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR EMBRYO INCUBATORS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 31 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR EMBRYO INCUBATORS, BY REGION, 2022-2030 (THOUSAND UNITS)
  • TABLE 32 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SPERM ANALYZER SYSTEMS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 33 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SPERM ANALYZER SYSTEMS, BY REGION, 2022-2030 (THOUSAND UNITS)
  • TABLE 34 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MICROMANIPULATORS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 35 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MICROMANIPULATORS, BY REGION, 2022-2030 (THOUSAND UNITS)
  • TABLE 36 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 37 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 38 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 39 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR EMBRYO CULTURE MEDIA, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 40 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CRYOPRESERVATION MEDIA, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 41 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SEMEN PROCESSING MEDIA, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 42 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR OVUM PROCESSING MEDIA, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 43 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SUPPLEMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 44 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 45 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 46 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CULTURE DISHES & PLATES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 47 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR STORAGE CONTAINERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 48 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CRYOVIALS & TUBES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 49 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR OTHER CONSUMABLES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 50 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 51 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR FEMALE PATIENTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 52 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MALE PATIENTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 53 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 54 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 55 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR HOSPITALS & SURGERY CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 56 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 57 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CRYOBANKS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 58 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 59 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 60 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 61 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 62 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 63 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 64 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 66 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 67 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 68 US: KEY MACROECONOMIC INDICATORS
  • TABLE 69 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 70 US: IVF ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 71 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 72 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 73 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 74 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 75 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 76 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 77 CANADA: KEY MACROECONOMIC INDICATORS
  • TABLE 78 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 79 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 80 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 81 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 82 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 83 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 84 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 85 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 86 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 87 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 88 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 89 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 90 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 91 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 92 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 93 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 94 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 95 GERMANY: KEY MACROECONOMIC INDICATORS
  • TABLE 96 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 97 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 98 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 99 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 100 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 101 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 102 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 103 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 104 UK: KEY MACROECONOMIC INDICATORS
  • TABLE 105 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 106 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 107 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 108 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 109 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 110 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 111 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 112 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 113 FRANCE: KEY MACROECONOMIC INDICATORS
  • TABLE 114 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 115 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 116 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 117 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 118 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 119 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 120 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 121 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 122 ITALY: KEY MACROECONOMIC INDICATORS
  • TABLE 123 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 124 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 125 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 126 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 127 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 128 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 129 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 130 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 131 SPAIN: KEY MACROECONOMIC INDICATORS
  • TABLE 132 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 133 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 134 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 135 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 136 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 137 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 138 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 139 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 140 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 141 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 142 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 143 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 144 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 145 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 146 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 147 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 148 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 152 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 154 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 156 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 157 CHINA: KEY MACROECONOMIC INDICATORS
  • TABLE 158 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 159 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 160 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 161 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 162 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 163 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 164 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 165 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 166 JAPAN: KEY MACROECONOMIC INDICATORS
  • TABLE 167 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 168 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 169 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 170 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 171 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 172 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 173 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 174 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 175 INDIA: KEY MACROECONOMIC INDICATORS
  • TABLE 176 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 177 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 178 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 179 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 180 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 181 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 182 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 183 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 184 AUSTRALIA: KEY MACROECONOMIC INDICATORS
  • TABLE 185 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 186 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 187 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 188 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 189 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 190 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 191 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 192 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 193 SOUTH KOREA: KEY MACROECONOMIC INDICATORS
  • TABLE 194 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 195 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 196 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 197 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 198 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 199 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 200 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 201 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 202 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 203 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 204 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 205 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 206 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 207 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 208 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 209 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 210 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 211 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 212 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 213 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 214 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 215 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 216 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 217 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 218 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 219 BRAZIL: KEY MACROECONOMIC INDICATORS
  • TABLE 220 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 221 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 222 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 223 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 224 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 225 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 226 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 227 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 228 MEXICO: KEY MACROECONOMIC INDICATORS
  • TABLE 229 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 230 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 231 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 232 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 233 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 234 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 235 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 236 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 237 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 238 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 239 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 240 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 241 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 242 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 243 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 244 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 245 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 246 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 247 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 248 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 249 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 250 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 251 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 252 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 253 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 254 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 255 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2030 (USD MILLION)
  • TABLE 256 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 257 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 258 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 259 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022-2030 (USD MILLION)
  • TABLE 260 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, JANUARY 2021-MARCH 2025
  • TABLE 262 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 263 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: REGION FOOTPRINT
  • TABLE 264 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: TYPE FOOTPRINT
  • TABLE 265 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PRODUCT TYPE FOOTPRINT
  • TABLE 266 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PATIENT TYPE FOOTPRINT
  • TABLE 267 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: END-USER FOOTPRINT
  • TABLE 268 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 269 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 270 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PRODUCT LAUNCHES, JANUARY 2021-MARCH 2025
  • TABLE 271 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 272 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021-MARCH 2025
  • TABLE 273 COOPERSURGICAL INC.: COMPANY OVERVIEW
  • TABLE 274 COOPERSURGICAL INC.: PRODUCTS OFFERED
  • TABLE 275 COOPERSURGICAL INC.: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 276 FUJIFILM IRVINE SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 277 FUJIFILM IRVINE SCIENTIFIC: PRODUCTS OFFERED
  • TABLE 278 FUJIFILM IRVINE SCIENTIFIC: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 279 FUJIFILM IRVINE SCIENTIFIC: OTHER DEVELOPMENTS, JANUARY 2021-MARCH 2025
  • TABLE 280 VITROLIFE: COMPANY OVERVIEW
  • TABLE 281 VITROLIFE: PRODUCTS OFFERED
  • TABLE 282 VITROLIFE: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 283 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 284 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 285 COOK MEDICAL INC.: COMPANY OVERVIEW
  • TABLE 286 COOK MEDICAL INC.: PRODUCTS OFFERED
  • TABLE 287 COOK MEDICAL INC.: PRODUCT LAUNCHES, JANUARY 2021-MARCH 2025
  • TABLE 288 COOK MEDICAL INC.: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 289 HAMILTON THORNE: COMPANY OVERVIEW
  • TABLE 290 HAMILTON THORNE: PRODUCTS OFFERED
  • TABLE 291 HAMILTON THORNE: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 292 KITAZATO CORPORATION: COMPANY OVERVIEW
  • TABLE 293 KITAZATO CORPORATION: PRODUCTS OFFERED
  • TABLE 294 KITAZATO CORPORATION: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 295 ESCO MICRO PTE. LTD.: COMPANY OVERVIEW
  • TABLE 296 ESCO MICRO PTE. LTD.: PRODUCTS OFFERED
  • TABLE 297 ESCO MICRO PTE. LTD.: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 298 FERTIPRO NV: COMPANY OVERVIEW
  • TABLE 299 FERTIPRO NV: PRODUCTS OFFERED
  • TABLE 300 GENEA BIOMEDX: COMPANY OVERVIEW
  • TABLE 301 GENEA BIOMEDX: PRODUCTS OFFERED
  • TABLE 302 GENEA BIOMEDX: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 303 LENUS PHARMA GESMBH: COMPANY OVERVIEW
  • TABLE 304 LENUS PHARMA GESMBH: PRODUCTS OFFERED
  • TABLE 305 LENUS PHARMA GESMBH: PRODUCT LAUNCHES, JANUARY 2021-MARCH 2025
  • TABLE 306 ZITA WEST: COMPANY OVERVIEW
  • TABLE 307 ZITA WEST: PRODUCTS OFFERED
  • TABLE 308 EXELTIS USA, INC.: COMPANY OVERVIEW
  • TABLE 309 EXELTIS USA, INC.: PRODUCTS OFFERED
  • TABLE 310 VITABIOTICS LTD.: COMPANY OVERVIEW
  • TABLE 311 VITABIOTICS LTD.: PRODUCTS OFFERED
  • TABLE 312 ADVACARE PHARMA: COMPANY OVERVIEW
  • TABLE 313 ADVACARE PHARMA: PRODUCTS OFFERED
  • TABLE 314 FAIRHAVEN HEALTH: COMPANY OVERVIEW
  • TABLE 315 SHANGHAI UNICORN MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 316 GYNEMED GMBH & CO. KG: COMPANY OVERVIEW
  • TABLE 317 INVITROCARE INC.: COMPANY OVERVIEW
  • TABLE 318 IVFTECH: COMPANY OVERVIEW
  • TABLE 319 LABIVF ASIA PTE LTD.: COMPANY OVERVIEW
  • TABLE 320 COAST SCIENCE: COMPANY OVERVIEW
  • TABLE 321 BIOIMAGER INC.: COMPANY OVERVIEW
  • TABLE 322 SHIVANI SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 323 MINITUB GMBH: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: COOPERSURGICAL INC., 2024
  • FIGURE 8 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION
  • FIGURE 9 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEMAND-SIDE MARKET SIZE ESTIMATION
  • FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS, 2025-2030
  • FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 12 DATA TRIANGULATION
  • FIGURE 13 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 GEOGRAPHICAL SNAPSHOT OF ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
  • FIGURE 18 INCREASING INFERTILITY WORLDWIDE TO DRIVE MARKET
  • FIGURE 19 IVF SEGMENT AND CHINA DOMINATED ASIA PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET IN 2024
  • FIGURE 20 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 21 ASIA PACIFIC TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 22 DEVELOPING MARKETS TO HAVE HIGHER CAGR DURING FORECAST PERIOD
  • FIGURE 23 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 24 AVERAGE AGE OF FIRST-TIME MOTHERS IN US, 2001-2023
  • FIGURE 25 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
  • FIGURE 26 AVERAGE SELLING PRICE TREND OF SUPPLEMENTS, BY REGION, 2022-2024 (USD)
  • FIGURE 27 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 28 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 29 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 30 INVESTMENT AND FUNDING SCENARIO, 2019-2023
  • FIGURE 31 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023
  • FIGURE 32 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023 (USD MILLION)
  • FIGURE 33 PATENT ANALYSIS, JANUARY 2014-DECEMBER 2024
  • FIGURE 34 PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS
  • FIGURE 36 KEY BUYING CRITERIA FOR TOP TWO END USERS
  • FIGURE 37 AI USE CASES
  • FIGURE 38 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SNAPSHOT
  • FIGURE 39 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SNAPSHOT
  • FIGURE 40 REVENUE ANALYSIS OF TOP PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, 2020-2024 (USD MILLION)
  • FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, 2024
  • FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025
  • FIGURE 43 EV/EBITDA OF KEY VENDORS, 2025
  • FIGURE 44 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 45 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 46 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 47 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 48 COOPERSURGICAL INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 49 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2024)
  • FIGURE 50 VITROLIFE: COMPANY SNAPSHOT (2024)
  • FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!